JP2017532308A - 化学療法誘発性下痢を含む消化管粘膜炎を治療するためのエルシグルチドの使用 - Google Patents

化学療法誘発性下痢を含む消化管粘膜炎を治療するためのエルシグルチドの使用 Download PDF

Info

Publication number
JP2017532308A
JP2017532308A JP2017513522A JP2017513522A JP2017532308A JP 2017532308 A JP2017532308 A JP 2017532308A JP 2017513522 A JP2017513522 A JP 2017513522A JP 2017513522 A JP2017513522 A JP 2017513522A JP 2017532308 A JP2017532308 A JP 2017532308A
Authority
JP
Japan
Prior art keywords
chemotherapy
ersigglutide
administration
cycle
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017513522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532308A5 (enExample
Inventor
ジョルジーノ ルーベン
ジョルジーノ ルーベン
ロンコローニ シモーナ
ロンコローニ シモーナ
カルカニール セルマ
カルカニール セルマ
トレント ファビオ
トレント ファビオ
スペツィア リッカルド
スペツィア リッカルド
モレーシノ チェチーリア
モレーシノ チェチーリア
ボイイ クヌスン カーステン
ボイイ クヌスン カーステン
Original Assignee
ヘルシン ヘルスケア ソシエテ アノニム
ヘルシン ヘルスケア ソシエテ アノニム
ジーランド ファーマ アクティーゼルスカブ
ジーランド ファーマ アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘルシン ヘルスケア ソシエテ アノニム, ヘルシン ヘルスケア ソシエテ アノニム, ジーランド ファーマ アクティーゼルスカブ, ジーランド ファーマ アクティーゼルスカブ filed Critical ヘルシン ヘルスケア ソシエテ アノニム
Publication of JP2017532308A publication Critical patent/JP2017532308A/ja
Publication of JP2017532308A5 publication Critical patent/JP2017532308A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017513522A 2014-09-10 2015-09-02 化学療法誘発性下痢を含む消化管粘膜炎を治療するためのエルシグルチドの使用 Pending JP2017532308A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048520P 2014-09-10 2014-09-10
US62/048,520 2014-09-10
PCT/IB2015/001922 WO2016038455A1 (en) 2014-09-10 2015-09-02 Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea

Publications (2)

Publication Number Publication Date
JP2017532308A true JP2017532308A (ja) 2017-11-02
JP2017532308A5 JP2017532308A5 (enExample) 2018-10-11

Family

ID=54548212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513522A Pending JP2017532308A (ja) 2014-09-10 2015-09-02 化学療法誘発性下痢を含む消化管粘膜炎を治療するためのエルシグルチドの使用

Country Status (18)

Country Link
US (1) US20160067311A1 (enExample)
EP (1) EP3191115A1 (enExample)
JP (1) JP2017532308A (enExample)
KR (1) KR20170052661A (enExample)
CN (1) CN107073081A (enExample)
AR (1) AR103119A1 (enExample)
AU (1) AU2015313919A1 (enExample)
BR (1) BR112017004577A2 (enExample)
CA (1) CA2959110A1 (enExample)
CL (1) CL2017000563A1 (enExample)
EA (1) EA201790552A1 (enExample)
IL (1) IL250928A0 (enExample)
MA (1) MA40623A (enExample)
MX (1) MX2017003166A (enExample)
PH (1) PH12017500426A1 (enExample)
SG (1) SG11201701690WA (enExample)
TW (1) TW201613634A (enExample)
WO (1) WO2016038455A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170087216A1 (en) * 2015-09-17 2017-03-30 Helsinn Healthcare Sa Therapeutic Uses of Elsiglutide
US11389424B2 (en) 2017-03-09 2022-07-19 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
IL271245B2 (en) * 2017-06-16 2023-10-01 Zealand Pharma As Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2
MX2022016367A (es) * 2020-06-19 2023-01-30 Napo Pharmaceuticals Inc Metodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia.
CN115054683B (zh) * 2022-05-19 2023-06-09 唐颢 胰高血糖素样肽-2在制备缓解阿霉素心脏毒性药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013189436A (ja) * 2005-05-04 2013-09-26 Zealand Pharma As グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200709027B (en) * 2005-04-22 2009-01-28 Novacea Inc Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin D compounds or mimics thereof
EP2314616A1 (en) * 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013189436A (ja) * 2005-05-04 2013-09-26 Zealand Pharma As グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUPPORTIVE CARE IN CANCER, ABSTRACTS OF THE 2014 INTERNATIONAL MASCC/ISOO SYMPOSIUM, 2014.06.26-28,, JPN6019022415, ISSN: 0004200286 *

Also Published As

Publication number Publication date
CA2959110A1 (en) 2016-03-17
MX2017003166A (es) 2017-06-19
MA40623A (fr) 2016-03-17
CL2017000563A1 (es) 2017-09-29
AU2015313919A1 (en) 2017-03-16
AR103119A1 (es) 2017-04-19
KR20170052661A (ko) 2017-05-12
CN107073081A (zh) 2017-08-18
BR112017004577A2 (pt) 2018-01-23
TW201613634A (en) 2016-04-16
PH12017500426A1 (en) 2017-07-31
EA201790552A1 (ru) 2017-08-31
US20160067311A1 (en) 2016-03-10
SG11201701690WA (en) 2017-04-27
WO2016038455A1 (en) 2016-03-17
IL250928A0 (en) 2017-04-30
EP3191115A1 (en) 2017-07-19

Similar Documents

Publication Publication Date Title
Hofland et al. Management of carcinoid syndrome: a systematic review and meta-analysis
ES2836424T3 (es) Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
US20160074390A1 (en) Human dosing of phosphatase inhibitor
KR20180043356A (ko) 담관암의 치료법
Shumaker et al. food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers
US20160067311A1 (en) Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
EP4168008B1 (en) A combination of belzutifan and lenvatinib for use in treating cancer
Quoix et al. First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule
US20260053791A1 (en) Use of tivozanib to treat subjects with refractory cancer
ES2984487T3 (es) Uso combinado de marizomib y bevacizumab para el tratamiento de cánceres del sistema nervioso central (SNC)
KR20140009212A (ko) 신경내분비 종양의 치료방법
Rebattu et al. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer
Xu et al. 177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial
US11000518B2 (en) Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer
US20120196828A1 (en) Sensitization of cancer cells to treatment
WO2021140478A1 (en) Combination therapy for treating cancer
Fiedler et al. Phase I trial of SU14813 in patients with advanced solid malignancies
WO2016161615A1 (en) Method for treating cancer
Kim et al. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer
US20230085602A1 (en) Pdac treatment regimen
US20190117655A1 (en) Treatment of Biliary Duct Cancer
AU2020454132A1 (en) Methods and compositions for treating chemotherapy-induced diarrhea
Park et al. Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer
Comella et al. Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience
US20170333554A1 (en) Dosing regimen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200128